Table 1.
Characteristic of infants who underwent assessment at 5-years of age.
| Characteristic | n = 84 |
|---|---|
| Gestational Age, weeksa | 27 ± 2 |
| Birth weight, ga | 933 ± 256 |
| Growth restriction for weight at birth | 7 (8.3%) |
| Growth restriction for occipito frontal circumference at birth | 12 (14.3%) |
| Male sex | 42 (50%) |
| Antenatal steroids | 67 (79.8%) |
| 5-min APGAR scorea | 6.2 ± 2.0 |
| Clinical Risk Index for Babies scorea | 4.1 ± 3.6 |
| Ventilator daysb | 3 (1–18) |
| Total parenteral nutrition daysb | 17 (11–32) |
| Patent ductus arteriosus requiring treatment | 39 (46.4%) |
| Necrotizing enterocolitis | 6 (7.1%) |
| Retinopathy of prematurity | 5 (6%) |
| Chronic lung disease | 28 (33.3%) |
| Intraventricular hemorrhage on cranial ultrasound | 33 (39.3%) |
| Grade I | 6 (7.1) |
| Grade II | 18 (21.4) |
| Grade III | 2 (2.4%) |
| Grade IV | 7 (8.3%) |
| Periventricular leukomalacia on cranial ultrasound | 6 (7.1%) |
| Cerebellar hemorrhage on magnetic resonance imaging | 17 (20.2%) |
| Grade I | 8 (9.5%) |
| Grade II | 4 (4.8%) |
| Grade III | 3 (3.6%) |
| Grade IV | 2 (2.4%) |
| Anesthesia exposure | 18 (21.4%) |
| Inotrope exposure | 19 (22.6%) |
| Fentanyl exposure | 62 (73.8%) |
| Morphine exposure | 12 (14.3%) |
| Midazolam exposure | 15 (17.9%) |
| Dexamethasone exposure | 8 (9.5%) |
| Hydrocortisone exposure | 15 (17.9%) |
| Social risk compositeb | 1.5 (0-3) |
| Income to need ratiob | 1.2 (0.8-2.4) |
| McMaster Family Assessment Deviceb | 1.4 (1.1-1.8) |
a
Mean ± standard deviation;
b
Median (interquartile range).